Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
REPROS THERAPEUTICS INC. (RPRX)
|
Add to portfolio |
|
|
|
| Price: |
$40.74
| | Metrics |
| OS: |
39.6
|
M
| |
|
|
| Market cap: |
$1.61
|
B
| |
|
|
|
Net cash:
|
$1.81
|
M
| |
$0.05
|
per share
|
|
EV:
|
$1.61
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($13.3)
|
M
| |
|
|
|
EBIT
|
($13.3)
|
M
| |
|
|
| EPS |
($0.16)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.6 |
| Revenue growth | 327.3% | 22.2% | 0.0% | 200.0% | 50.0% | -99.5% | -23.6% | 27.3% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 12.8 | 24.1 | 27.1 | 23.7 | 14.1 | 8.7 | 2.9 | 23.1 |
| General and administrative | 4.6 | 5.1 | 5.4 | 4.8 | 4.8 | 3.8 | 2.3 | 4.7 |
| EBIT | -17.3 | -29.2 | -32.5 | -28.5 | -18.9 | -12.5 | -5.2 | -27.8 |
| EBIT margin | -36851.1% | -265481.8% | -361600.0% | -316388.9% | -631566.7% | -624650.0% | -1232.5% | -5042.6% |
| Pre-tax income | -17.3 | -29.2 | -32.5 | -28.5 | -18.9 | -12.5 | -4.8 | -27.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -17.3 | -29.2 | -32.5 | -28.5 | -18.9 | -12.5 | -4.8 | -27.2 |
| Net margin | -36751.1% | -265381.8% | -361500.0% | -316288.9% | -631466.7% | -624550.0% | -1132.5% | -4942.6% |
| |
| Diluted EPS | ($0.70) | ($1.20) | ($1.39) | ($1.37) | ($1.23) | ($1.04) | ($0.59) | ($6.28) |
| Shares outstanding (diluted) | 24.7 | 24.3 | 23.4 | 20.8 | 15.3 | 12.0 | 8.1 | 4.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|